Home  /  JOINT ACTION 3 (Page 4)

This is the pharmaceutical Joint Assessment PTJA06 – on polatuzumab vedotin for the treatment of relapsed/refractory DLBCL. In January 2020, The European Commission granted conditional marketing authorisation for Polivy® (polatuzumab vedotin), in combination with bendamustine plus MabThera® (rituximab) (BR), for

EUnetHTA recently started a new Collaborative Assessment of different surgical methods to treat morbid obesity  To find out about participation, please read more here. Input submissions will be received through EOB, 20th March, 2020 EUnetHTA deems patient input very important in the production of

The aim of this methodological guideline is to provide an up-to-date and transparent overview of the whole information retrieval process for Systematic reviews and HTAs on clinical effectiveness. In particular, the requirements presented in this methodological guideline aim to provide orientation

The final project plan  of the relative effectiveness of  ‘Brolucizumab for the treatment of adults with neovascular (wet) age-related macular degeneration (AMD)' is now available for access. The final assessment report will be published on 12th March, 2020. Below is the documentation

The final project plan of the assessment on polatuzumab is now available. The final assessment report will be published on 13th February, 2020. Please access the final project plan at the following link: PTJA06 Final Project Plan​

The final assessment report and related documents for the Other Technologies Collaborative Assessment 'Lithium triborate (LBO) laser for photoselective vaporisation of the prostate (PVP) in the treatment of benign prostatic hyperplasia (BPH)' are now available for access. The present assessment addressed